• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [19518 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2015     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) [Bioquell airborne disinfection system]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Bioresorbable peripheral stents]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Bisphosphonates as treatment for breast cancer]
2009     Committee for New Health Technology Assessment (CNHTA) [Bladder tumor antigen test]
2008     Haute Autorite de sante (HAS) [Bladder volume measurement with portable ultrasound device]
2011     The Swedish Council on Health Technology Assessment (SBU) [Bleeding peptic ulcer]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab - assessment according to §35a (para. 1, sentence 10) Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Blinatumomab (acute lymphoblastic leukaemia) - assessment according to §35a (para. 1., sentence 10) Social Code Book V (expiry of the decision)]
2005     Finnish Office for Health Care Technology Assessment (Finohta) [Blood glucose self-monitoring in diabetes management]
2012     The Swedish Council on Health Technology Assessment (SBU) [Blood test for early diagnosis of Alzheimer's disease]
2019     Andalusian Health Technology Assessment Area (AETSA) [Blood test for the early diagnosis of pancreatic cancer. CancerSEEK]
2011     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Boceprevir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Bone graft substitutes in traumatology]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Bone marrow stem cell therapy for orthopedic conditions]
2013     Haute Autorite de sante (HAS) [Bone substitutes]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bosutinib: assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)]
2011     Andalusian Health Technology Assessment Area (AETSA) [Botulinum toxin A in the treatment of morbid obesity]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Botulinum toxin for the treatment of headache]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Botulinum toxin in adult patients with dystonia]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Botulinum toxin use in adults and children with urinary tract function disorders]
1999     Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS) [Brachytherapy and prostate cancer]
2008     Committee for New Health Technology Assessment (CNHTA) [BRAF gene mutation analysis]
2011     Committee for New Health Technology Assessment (CNHTA) [BRAF Gene, Mutation(Peptide Nucleic Acid Mediated Real-time PCR Clamping Method)]
2008     Committee for New Health Technology Assessment (CNHTA) [BRAF V600E mutation]
2011     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Brain injury rehabilitation - a health technology assessment]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 08: Drug-eluting stents and bare-metal stents in the treatment of coronary artery disease]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 09: Statins for the prevention of cardiovascular events]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 10: Rituximab in the treatment of diffuse large B-cell non-Hodgkin's lymphoma (DLBCL)]
2010     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 11: Positron Emission Tomography (PET) in the diagnosis, staging and restaging of patients with colorectal cancer]
2010     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 12: Clinical strategies for smoking cessation]
2010     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [BRATS 13: The use of insulin glargine and insulin detemir to control type 1 diabetes mellitus]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Bravo pH monitoring in gastroesophageal reflux]
2013     Andalusian Health Technology Assessment Area (AETSA) [Breast cancer ablation with radiofrequency. Systematic review]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brentuximab Vedotin - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brentuximab vedotin (Hodgkin lymphoma with an increased risk of relapse or progression) - assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Brentuximab vedotin for Hodgkin´s lymphoma]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brivaracetam - addendum to commission A16-08]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brivaracetam - benefit assessment according to §35a Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brodalumab (plaque psoriasis) – benefit assessment according to §35a Social Code Book V]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Brolucizumab in neovascular age-related macular degeneration]
2008     Committee for New Health Technology Assessment (CNHTA) [Bronchial provocation test]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Bronchial thermoplasty in severe asthma]
2012     Basque Office for Health Technology Assessment (OSTEBA) [Budget impact analysis of a telemedicine procedure in quality assurance programs for spirometry in patients with COPD]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Budget impact analysis of increasing kidney transplantation in Québec]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Building planning and infection control: hand hygiene dispensers and individual bathrooms in residential and long-term care centres]
2009     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bupropion, mirtazapine, and reboxetine in the treatment of depression]
2010     National Evidence-based Healthcare Collaborating Agency (NECA) [Burden of irritable bowel syndrome in Korea]
2013     Haute Autorite de sante (HAS) [Bypass prostheses]
2012     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Bypass surgery performed with or without the use of heart-lung machine]
2011     Committee for New Health Technology Assessment (CNHTA) [C-11-acetate positron emission tomography, positron emission tomography/computed tomography]
2020     Andalusian Health Technology Assessment Area (AETSA) [C-Reactive Protein point-of-care testing (CRP-POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections]
2012     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabazitaxel - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Cabazitaxel, abiraterone and enzalutamide in metastatic castration-resistant prostate cancer not responding to docetaxel]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib - assessment according to section 35a (paragraph 1, sentence 10) Social Code Book V (dossier assessment)]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (renal cell carcinoma) - addendum to order A16-69]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (renal cell carcinoma) - benefit assessment according to §35a Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2005     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Caesarean section on maternal request: a health technology assessment]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Calreticulin gene mutation testing in myeloproliferative neoplasms]
2011     Committee for New Health Technology Assessment (CNHTA) [Camera manipulating robot assisted endoscopic surgery]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Canagliflozin, empagliflozin and dapagliflozin (SGLT-2) for patients with type 2 diabetes]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Canagliflozin, empagliflozin and dapagliflozin in type 2 diabetes patients]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Canagliflozin: benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Canagliflozin/metformin. Benefit assessment according to section 35a Social Code Book V (dossier assessment)]
2013     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Canaloplasty for open angle glaucoma]
2001     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Cancer of the colon and rectum - diagnosis and screening]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Cannabinoids in patients with autism spectrum disorders]
2005     Andalusian Health Technology Assessment Area (AETSA) [Cannabis therapeutic utility]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Caplacizumab (acquired thrombotic thrombocytopenic purpura) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2007     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Capsule endoscopies of the small intestine - a health technology assessment]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Cardiac contractility modulation for heart failure- 2nd Update 2010]
2010     Haute Autorite de sante (HAS) [Cardiac markers in coronary disease and heart failure in outpatient medicine]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Cardiac rehabilitation - a health technology assessment: evidence from the literature and the DANREHAB trial]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Cardiac resynchronization therapy: multi-site pacemaker use]
2010     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Cardiac resynchronization therapy. Economic evaluation]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Cardiac surgery registry. An international review]
2009     Committee for New Health Technology Assessment (CNHTA) [Cardio detect(h-FABP)]
2018     Andalusian Health Technology Assessment Area (AETSA) [Cardiopoietic stem cells for the treatment of heart failure secondary to myocardial ischemia]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Cardiopulmonary resuscitation in COVID-19 patients]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Cardiovascular prevention at old ages, competing risks, competing costs, frailty and indirect medical costs]
2013     Andalusian Health Technology Assessment Area (AETSA) [CardioWest™ TAH-t. Total artificial heart]
2020     Andalusian Health Technology Assessment Area (AETSA) [Care model for women with endometriosis. Systematic review of clinical practice guidelines]
2017     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Care needs assessment tools]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib - assessment according to §35a (para. 1, sentence 10) Social Code Book V]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib (multiple myeloma; combination with dexamethasone alone) – assessment according to § 35a (para.1, sentence 10) Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Carfilzomib (multiple myeloma) – benefit assessment according to §35a Social Code Book V]
2008     Committee for New Health Technology Assessment (CNHTA) [Caries diagnosis with laser fluorescence(Diagnodent)]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Carotid echo doppler for plaque area measurement in cardiovascular risk stratification]
2011     Basque Office for Health Technology Assessment (OSTEBA) [Case and control study: efficiency of psychoeducational treatment of the overload experienced by family members of bipolar patients]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Case finding in osteoporosis, how to implement current guidelines? A randomized comparison of two implementation strategies in general practice]
2012     The Swedish Council on Health Technology Assessment (SBU) [Case finding, diagnosis and follow up of patients with affective disorders]
2012     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Catalan arthroplasty register. 2nd report (data 2005-2010)]
2010     The Swedish Council on Health Technology Assessment (SBU) [Catheter ablation for atrial fibrillation (update)]
2005     The Swedish Council on Health Technology Assessment (SBU) [Catheter ablation of atrial fibrillation - early assessment briefs (Alert)]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Catheter-directed mechanical thrombolysis in thromboembolic disease]
2008     Committee for New Health Technology Assessment (CNHTA) [CBFB/MYH11 rearrangement, Quantification [Real-time RT-PCR]]
2009     Committee for New Health Technology Assessment (CNHTA) [CD4 lymphocyte activity (bioluminescent assay)]